Approval of Lenvatinib as a therapy medication for Advanced Kidney Cancer

1
Approval of Lenvatinib As A Therapy
Medication For Advanced Kidney Cancer
2
Lenvatinib commonly known as Lenvima
(manufactured by Eisai), was approved by US Food
and Drug Administration in 2016 for the treatment
of advanced kidney cancer. This medication has
been approved solely for the patients whose
cancer has progressed even after receiving
treatment from medications which blocks the
tumour growth.
3
Lenvima is classified under the category of
targeted therapy. The main aim for the
medication which comes under this category is to
target something specific to the cancer cells.
Thus leading to less side effects caused by
damage to healthy cells.
4
Lenvima cost information Lenvatinib mechanism of
action Lenvatinib works in two phases They
create an interference in cells protein that
promotes cell division. They block the VEGF
receptor in damaged cells, these cells are
responsible for the process called angiogenesis
i.e. development of supply of blood to the
tumour. Thereby cutting out the source of
nutrients for the tumour cell.
5
In laymans terms this medication works on two
stages Cells Lenvatinib blocks the signals
that allow the cancer cells to survive and
multiply. Blood vessels Lenvatinib blocking
the signals in blood cells, makes a hindrance in
the survival and growth of blood vessels affected
by tumour.
6

• Some possible side effects of Lenvima /
  Lenvatinib?
• Lenvima / Lenvatinib Side effects (Common)
• Constipation
• Nausea
• Rash
• Peripheral Edema
• Decreased Appetite
• Protein In The Urine
• Diarrhea

7

• Fatigue
• High Blood Pressure
• Muscle Or Joint Aches
• Weight Decrease
• Stomatitis/Oral Inflammation
• Cough
• Abdominal Pain
• Dyspnea

8

• Lenvatinib / Lenvima Side effects (Rare/Serious)
  
• fast or irregular heartbeat or fainting
• high blood pressure
• blood clots
• heart problems like decreased ejection fraction
  or heart failure
• changes in kidney function

9
In case any of the side effects becomes
unbearable or uncontrollable, contact your Doctor
/ Hospital immediately.   On 2016, US FDA
approved two similar medications for advanced
kidney cancer - Lenvatinib (Brand Lenvima) in
combination with Everolimus (Brand Afinitor) and,
cabozantinib (brand Cabometyx).
10
Both Lenvima and Cabometyx are multi-targeted
agents in the cancer cells that hinder the
activity of severalmolecular targets. Both
theses drugs block the protein activity involved
in angiogenesis which further blocks the growth
and survival of tumor cells.
11
Lenvatinib approval was granted on the basis of a
Randomised phase 2 clinical trial. This trial
considered treatment of patients with 3 different
medications Lenvatinib in combination with
everolimus (Group 1), lenvatinib alone (higher
dose as compared to group 1 lenvatinib) (Group 2)
and everolimus alone (group 3).
12
After the trial was finished, Patients in group 1
had a median progression free survival of 14.6
months as compared to patients in group 3 who
had a progression free survival of 5.5 months.
Lenvatinib cost information
13
According to the Food and Drug Administration,
the updated data from the above trial indicated
an upward trend in overall survival as well as
progression free survival for the patients who
were enrolled in group 1 lenvatinib in
combination with everolimus although this trend
was not able to reach statistical significance.
14
The information provided on the page is meant for
the purpose of being helpful and educational. It
should not be considered as medical
advice.   lenvatinib side effects, lenvima side
effects, lenvatinib mechanism of action, lenvima
cost, lenvatinib cost
15
Contact Us Website- www.CancerCurePharmacy.com
Email- CustomerCare_at_CancerCurePharmacy.com